At Avocet Biosciences, we stand at the forefront of medical research pioneering new avenues in science and testing innovative ideas to develop treatments with the potential to save lives on a global scale.

Leading the forefront of biotechnology innovation

Revolutionizing the battle against viral diseases

Creating a positive global impact and elevating the quality of life for all

We envision a world where both present and future viral threats are met with swift, precise, and highly effective solutions.

Supported by

CEO/Co-founder
Elisabeth is clinician-scientist who initiated a patented molecular scissors platform in early 2020 against all current SARS-CoV2 variants & future Coronaviruses leading to the foundation of Avocet Bio. She spent 5 years as faculty at Harvard Medical School & meanwhile translated her basic cardiac research into a phase-II clinical therapeutic trial at UMG. Elisabeth hand-picked her diverse team to successfully develop the platform to mitigate future pandemics

Co-founder
Albert is a globally recognized virologist who played an important role in the identification of the MERS-CoV and two other human coronaviruses. Several of his antiviral therapies have already entered the clinic. Albert is also a successful serial entrepreneur who contributes firsthand experience of guiding a scientific idea through preclinical development and into the clinic.

Co-founder
Diane brings more than 2 decades of drug development and regulatory experience to Avocet Bio. She held executive positions and led international drug development teams to bring first in class products from idea to approval. She is a serial entrepreneur with a successful exit and supports inter-national biotech companies as board member & advisor. She will guide the Avocet Bio team on drug development, regulatory and corporate strategies.

Co-founder
Gerd is head of the Department of Cardiology and Pneumology at UMG and of the Heart Center Göttingen. He has a track record of bringing basic science discoveries to the clinic and he contributes his longstanding experience in organizing and performing clinical trials, both as a principal investigator and as a member of steering committees.

Co-founder
Michael is head of the Department of Nephrology and Rheumatology at UMG and led the Covid-19 non-ICU team during the pandemic. He has performed paradigm shifting research in the field of fibrosis for over 20 years. Michael spent 5 years as an assistant professor at Harvard Medical School and is a clinician-scientist at heart who brings hands-on expertise in antiviral patient care and beyond.

Chief Operating Officer
Sabine holds a PhD in cardiovascular science from the University Medical Center Göttingen and has been actively involved in developing the RNA based antiviral technology since the inception of the CRISPR/Cas13 antiviral therapy project. She is enthusiastic about entrepreneur-ship and drug development from laboratory research to clinical appli-cation and has been an integral part of Avocet Bio since day one.

Research Scientist
Nils graduated from the Ludwig-Maximilians-University (LMU), Munich, with an M.Sc. in Molecular and Cellular Biology. During the covid pandemic, he was the head of the student council for 2 years, managing the transition to online teaching. Here at Avocet Bio, Nils is looking forward to harness his lab and leadership expertise in the search for innovative RNA based antiviral therapies.

Chief Strategy Officer
Maximilian holds a PhD in Medical Research from Ludwig Maximilians University and brings extensive expertise in life sciences and molecular medicine. With a background spanning executive strategy planning and managing drug development programs, he excels in biopharmaceutical development and regulatory affairs. At Avocet Bio, his passion for operational excellence drives him to craft and implement pioneering strategic initiatives, propelling the company towards sustained growth.

Apply through the link below